Yau T K, Soong I S, Chan K, Chang A, Sze H, Yeung M W, Tung R, Lau S, Lee A
Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, 3 Lok Man Road, Chai Wan, Hong Kong SAR, People's Republic of China.
Breast. 2008 Feb;17(1):58-63. doi: 10.1016/j.breast.2007.06.007. Epub 2007 Sep 4.
Incorporating various new and conventional risk factors, the 2005 St Gallen risk categorization is a potentially useful prognostic tool for breast cancers. We conducted a retrospective study to evaluate its application in Hong Kong. Of the 902 included female breast cancers with median follow-up of 5.4 years, 7%, 63% and 30% patients were classified as low-, intermediate- and high-risk categories, respectively. Their corresponding 5-year distant disease-free survivals (DDFS) were 100%, 92% and 72%, respectively (p<0.00005). In the intermediate-risk category, node-positive patients had marginally inferior 5-year DDFS than node-negative patients (89% vs. 93%, p=0.0551). In the high-risk category, patients having HER2 overexpressed tumors and 1-3 positive nodes had significantly better DDFS than other patients with > or = 4 positive nodes (89% vs. 65%, p=0.0001). Overall, the 2005 St Gallen risk categorization had high prognostic value. However, the impact of HER2 overexpression might be affected by reproducibility of HER2 tests.
纳入各种新的和传统的风险因素后，2005年圣加仑风险分类法是一种对乳腺癌可能有用的预后工具。我们进行了一项回顾性研究以评估其在香港的应用情况。在纳入的902例女性乳腺癌患者中，中位随访时间为5.4年，分别有7%、63%和30%的患者被分类为低、中、高风险类别。其相应的5年远处无病生存率（DDFS）分别为100%、92%和72%（p<0.00005）。在中风险类别中，淋巴结阳性患者的5年DDFS略低于淋巴结阴性患者（89%对93%，p=0.0551）。在高风险类别中，HER2过表达肿瘤且有1-3个阳性淋巴结的患者的DDFS明显优于其他有≥4个阳性淋巴结的患者（89%对65%，p=0.0001）。总体而言，2005年圣加仑风险分类法具有较高的预后价值。然而，HER2过表达的影响可能会受到HER2检测可重复性的影响。
